Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1981 1
1985 1
1989 1
1990 1
1992 2
1993 1
1994 1
1995 3
1996 1
1997 4
1998 2
1999 8
2000 1
2001 5
2002 7
2003 5
2004 14
2005 8
2006 15
2007 17
2008 22
2009 22
2010 26
2011 44
2012 43
2013 67
2014 79
2015 86
2016 89
2017 53
2018 66
2019 76
2020 105
2021 112
2022 85
2023 82
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

992 results

Results by year

Filters applied: . Clear all
Page 1
The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Fleckenstein M, Mitchell P, Freund KB, Sadda S, Holz FG, Brittain C, Henry EC, Ferrara D. Fleckenstein M, et al. Ophthalmology. 2018 Mar;125(3):369-390. doi: 10.1016/j.ophtha.2017.08.038. Epub 2017 Oct 27. Ophthalmology. 2018. PMID: 29110945 Free article. Review.
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible loss of visual function. Geographic atrophy is defined by the presence of sharply demarcated atrophic lesions of the outer …
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversib …
Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3.
Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, Blodi BA, Bottoni F, Chakravarthy U, Chew EY, Csaky K, Danis RP, Fleckenstein M, Freund KB, Grunwald J, Hoyng CB, Jaffe GJ, Liakopoulos S, Monés JM, Pauleikhoff D, Rosenfeld PJ, Sarraf D, Spaide RF, Tadayoni R, Tufail A, Wolf S, Staurenghi G. Sadda SR, et al. Ophthalmology. 2018 Apr;125(4):537-548. doi: 10.1016/j.ophtha.2017.09.028. Epub 2017 Nov 2. Ophthalmology. 2018. PMID: 29103793 Free article.
AGE-RELATED MACULAR DEGENERATION.
Gheorghe A, Mahdi L, Musat O. Gheorghe A, et al. Rom J Ophthalmol. 2015 Apr-Jun;59(2):74-7. Rom J Ophthalmol. 2015. PMID: 26978865 Free PMC article. Review.
It is characterized by the appearance of drusen in the macula, accompanied by choroidal neovascularization (CNV) or geographic atrophy....
It is characterized by the appearance of drusen in the macula, accompanied by choroidal neovascularization (CNV) or geographic atr …
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. Jaffe GJ, et al. Ophthalmology. 2021 Apr;128(4):576-586. doi: 10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1. Ophthalmology. 2021. PMID: 32882310 Free article. Clinical Trial.
The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with geographic atrophy (GA) secondary to AMD (GATHER1 Study). DESIGN: International, prospective, randomized, double-masked, sham-con …
The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with …
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
BACKGROUND: Geographic atrophy is a leading cause of progressive, irreversible vision loss. ...INTERPRETATION: Pegcetacoplan, the first treatment approved by the US Food and Drug Administration for geographic atrophy, slowed geographic atroph …
BACKGROUND: Geographic atrophy is a leading cause of progressive, irreversible vision loss. ...INTERPRETATION: Pegcetacoplan, …
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system.
Bakri SJ, Bektas M, Sharp D, Luo R, Sarda SP, Khan S. Bakri SJ, et al. J Manag Care Spec Pharm. 2023 May;29(5-a Suppl):S2-S11. doi: 10.18553/jmcp.2023.29.5-a.s2. J Manag Care Spec Pharm. 2023. PMID: 37125931 Free PMC article.
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that first start in the outer retina and progressively expand to cover the macula and the fovea, the center of the macula, leading to irreversibl …
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that …
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG. Liao DS, et al. Ophthalmology. 2020 Feb;127(2):186-195. doi: 10.1016/j.ophtha.2019.07.011. Epub 2019 Jul 16. Ophthalmology. 2020. PMID: 31474439 Free article. Clinical Trial.
PURPOSE: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. ...
PURPOSE: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. ...
Age-Related Macular Degeneration: Epidemiology and Clinical Aspects.
Keenan TDL, Cukras CA, Chew EY. Keenan TDL, et al. Adv Exp Med Biol. 2021;1256:1-31. doi: 10.1007/978-3-030-66014-7_1. Adv Exp Med Biol. 2021. PMID: 33847996
Late AMD is divided into neovascular and atrophic forms, though these can coexist. The defining lesions are macular neovascularization and geographic atrophy, respectively. At this stage, visual symptoms are often severe and irreversible, and can comprise profoundly …
Late AMD is divided into neovascular and atrophic forms, though these can coexist. The defining lesions are macular neovascularization and …
COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHY: Review of Salient Functional Outcomes and Perspective.
Spaide RF, Vavvas DG. Spaide RF, et al. Retina. 2023 Jul 1;43(7):1064-1069. doi: 10.1097/IAE.0000000000003796. Retina. 2023. PMID: 36996460 Clinical Trial.
PURPOSE: To evaluate available rationale and outcomes of randomized trial results for complement inhibition for geographic atrophy. METHODS: Data from recently completed randomized trials of complement inhibition, particularly for pegcetacoplan and avacincaptad pego …
PURPOSE: To evaluate available rationale and outcomes of randomized trial results for complement inhibition for geographic atrophy …
Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning.
Vogl WD, Riedl S, Mai J, Reiter GS, Lachinov D, Bogunović H, Schmidt-Erfurth U. Vogl WD, et al. Ophthalmol Retina. 2023 Jan;7(1):4-13. doi: 10.1016/j.oret.2022.08.003. Epub 2022 Aug 7. Ophthalmol Retina. 2023. PMID: 35948209 Free article. Clinical Trial.
PURPOSE: To identify disease activity and effects of intravitreal pegcetacoplan treatment on the topographic progression of geographic atrophy (GA) secondary to age-related macular degeneration quantified in spectral-domain OCT (SD-OCT) by automated deep learning as …
PURPOSE: To identify disease activity and effects of intravitreal pegcetacoplan treatment on the topographic progression of geographic …
992 results